Clinical pharmacokinetics of simotinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC patients.

被引：1
|
作者：
Han, Xiaohong
Li, Ning
Hu, Xingsheng
Song, Yuanyuan
Zhang, Yan
Shi, Yuankai
机构：
[1] Chinese Acad Med Sci, Canc Inst Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Canc Inst Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e13575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13575
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
    Ruishan Wen
    Ying Chen
    Jinyu Long
    Xiulian Huang
    Yuxin Guo
    Baoquan Lin
    Zongyang Yu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 8307 - 8316
  • [42] Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC
    Ying, Hou-Qun
    Liao, Yu-Cui
    Luo, Yan-Ran
    Xiong, Gang
    Huang, Ying
    Nie, Ruo-Wei
    Xiong, Cui-Fen
    Cheng, Xue-Xin
    PHARMACOLOGICAL RESEARCH, 2021, 170
  • [43] Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC
    Tanvetyanon, Tawee
    Chen, Dung-Tsa
    Gray, Jhanelle E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Stock-Martineau, Sophie
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
  • [45] A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naive patients with advanced NSCLC.
    Lisberg, Aaron Elliott
    Cummings, Amy Lauren
    Goldman, Jonathan Wade
    Bornazyan, Krikor
    Reese, Nicholas Dean
    Wang, Tina
    Coluzzi, Paul
    Ledezma, Blanca A.
    Mendenhall, Melody A.
    Jones, Benjamin
    Madrigal, John
    Carroll, James M.
    Gukasyan, Jaklin
    Williams, Tawny
    Sauer, Lauren
    Wells, Courtney L.
    Hardy, Ariana R.
    Linares, Paulina J.
    Adame, Carlos R.
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
    Xu, Jianlin
    Jin, Bo
    Chu, Tianqing
    Dong, Xue
    Yang, Haitang
    Zhang, Yanwei
    Wu, Dan
    Lou, Yuqing
    Zhang, Xueyan
    Wang, Huiming
    Han, Baohui
    LUNG CANCER, 2016, 96 : 87 - 92
  • [47] Different genetic profiles of resistant and sensitive patients with EGFR wild type NSCLC undergoing tyrosine kinase inhibitor (TKI) treatment
    Ulivi, P. U.
    Chiadini, E. C.
    Dubini, A. D.
    Calistri, D. C.
    Puccetti, M. P.
    Burgio, M. A. B.
    Delmonte, A. D.
    Verlicchi, A. V.
    Gamboni, A. G.
    Papi, M. P.
    Zoli, W. Z.
    Crino, L. C.
    Dazzi, C. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 168 - 168
  • [48] Predictive value of intratumoral metabolic heterogeneity features for early treatment failure of tyrosine kinase inhibitor in patients with EGFR mutated NSCLC
    Ha, S.
    Park, S.
    Lee, S.
    Paeng, J.
    Keam, B.
    Kim, T.
    Kim, D.
    Heo, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S61 - S62
  • [49] A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK plus advanced/metastatic NSCLC
    Solomon, B. J.
    Millward, M.
    Kim, D-W.
    Park, E. K.
    Lin, J. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1034 - S1034
  • [50] Evaluation on efficacy of EGFR tyrosine kinase inhibitors in NSCLC patients: A meta-analysis of 68 randomized clinical trials
    Xu, Hongmei
    Minchella, Kaitlyn
    Zhou, Diansong
    Al-Huniti, Nidal
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S21 - S21
12345